Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CAP-Gly domain containing linker protein family member 4 (CLIP4) is a human protein encoded by the CLIP4 gene, characterized by two CAP-Gly (cytoskeleton-associated protein glycine-rich) domains and numerous ankyrin repeats[1][5]. These domains suggest a role in the regulation of microtubule dynamics and protein-protein interactions. CLIP4 is most highly expressed in the thyroid, adrenal cortex, atrioventricular node, and muscle tissues[1]. Although not canonically classified as a therapeutic target such as a receptor, enzyme, or transporter, CLIP4 has emerging importance in oncology research, particularly as a potential tumor suppressor or biomarker; its downregulation and promoter hypermethylation are linked to breast and colon cancers. There are no known drugs that directly target CLIP4, and it has not been implicated as a direct therapeutic target or drug mechanism site. Functional studies associate it with cytoplasmic microtubule organization and possible interactions with other microtubule-associated proteins such as MAPRE1, MAPRE2, and MAPRE3[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CAP-Gly domain containing linker protein family member 4 (CLIP4).